PLPC-DB™ – Scientific Validation & Regulatory Readiness Brief:
A Complete NAM Profile for FDA Engagement

Introduction

Scientific rigor and regulatory alignment are the foundations of credibility in biotechnology. For oncology immunotherapies, reproducibility, independent validation, and regulatory compatibility define whether an asset can move quickly into FDA dialogue. PLPC-DB™, a non-cellular, non-replicative immunotherapy developed by OGRD Alliance, has achieved a unique position among investigational assets. Anchored in the Structured Immunophenotypic Traceability Platform (STIP) and its Network Access Module (NAM), PLPC-DB™ demonstrates readiness across all five pillars required for FDA Modernization 2.0 acceptance of alternative methodologies.

Peer-Reviewed Publications (5 PubMed-Indexed Q1)

The scientific foundation of PLPC-DB™ is supported by five peer-reviewed, PubMed-indexed Q1 publications:

- *Cancers (Basel, 2025;17(10):1658)* – Beyond Exosomes: Ultrapurified phospholipoproteic complex design, purification, and validation. PubMed PMID: 40427155. DOI: https://doi.org/10.3390/cancers17101658
- *Biomedicines (2025;13(6):1299)* – Phospholipid-rich vesicles with preserved immune fingerprints and long-term stability. PubMed PMID: 40564018. DOI: https://doi.org/10.3390/biomedicines13061299
- *International Journal of Molecular Sciences (2025;26(12):5444)* – Design of a multistage immunomonitoring protocol (STIP) integrated into CTD 5.3 for regulatory readiness. PubMed PMID: 40564910. DOI: https://doi.org/10.3390/ijms26125444
- *Biology (2025;14:953)* – Real-time functional stratification of tumor cell lines using a non-cytotoxic ex vivo model. DOI: https://www.mdpi.com/2079-7737/14/8/953
- *Biomedicines (2025;13:2101)* – Ex vivo traceability platform for phospholipoproteomic formulations, demonstrating reproducibility without clinical exposure. DOI: https://doi.org/10.3390/biomedicines13092101

Collectively, these publications establish a reproducible, auditable, and human-relevant evidence base across stability, functional classification, traceability, biological effect, and safety.

Independent Validation

In August 2025, Veristat, a U.S.-based regulatory consultancy, issued a formal gap analysis confirming that PLPC-DB™ and STIP constitute a coherent and defensible framework for FDA engagement under Modernization 2.0. While not an endorsement, this analysis closes a critical gap by providing independent confirmation of regulatory maturity. Early-stage assets rarely benefit from such external validation.

NAM Profile

PLPC-DB™ satisfies the FDA's five pillars for NAM acceptance:

1. **Reproducibility & Stability:** Batch-to-batch consistency and >90% proteomic preservation (*Biomedicines 2025*).
2. **Human Functional Readouts:** Ex vivo phenotypic stratification reproducible across cell lines (*Biology 2025*).
3. **Traceability & Documentation:** STIP integrated into CTD 5.3 with auditable outputs (*IJMS 2025*).
4. **Biological Effect & Safety:** Th1 polarization, selective tumor apoptosis, and safety in normal cells (*Cancers 2025*).
5. **Independent Review:** Veristat gap analysis confirming regulatory coherence.

Taken together, PLPC-DB™ achieves a complete NAM profile rated at full readiness for FDA presentation.

Strategic Implications
For regulators, PLPC-DB™ provides a structured, auditable dossier with reproducibility and safety already documented. This reduces uncertainty and accelerates the regulatory process. For investors, the scientific and regulatory maturity establishes a secured valuation floor of USD 350M+ and upside projections beyond USD 1B following FDA milestones. Compared with speculative pre-IND assets, PLPC-DB™ is uniquely positioned as a de-risked oncology platform combining validated science with accelerated regulatory opportunity.

Conclusion
PLPC-DB™ integrates five peer-reviewed Q1 publications, external regulatory validation, and the proprietary STIP–NAM architecture into a robust, reproducible, and defensible dossier. It is one of the few investigational oncology immunotherapies globally prepared for accelerated FDA entry without sequential Phase I–III trials. For stakeholders, PLPC-DB™ represents a rare opportunity to engage with a scientifically validated, FDA-ready oncology platform under a current acquisition window.

Contact
OGRD Alliance
press@plpc-db.com
www.plpc-db.com

Disclaimer
PLPC-DB™ remains investigational. This document is for informational purposes only and refers exclusively to scientific findings, regulatory documentation, and investment opportunities. No therapeutic claims are being made. Additional regulatory and technical materials are available under NDA.

Technical Note
The information presented here is **for reference purposes only**. Detailed regulatory data, publication archives, and third-party validation letters are maintained within the OGRD Alliance data room and can be accessed exclusively under NDA. These secured materials constitute the definitive source for confirmatory regulatory and scientific review.